What's in IRCCS Eugenio Medea's pipeline?

IRCCS Eugenio Medea has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with IRCCS Eugenio Medea's portfolio?

Top competitors by shared drug class: Laboratoires NEGMA, Merck Sharp & Dohme LLC, The HIV Netherlands Australia Thailand Research Collaboration.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/irccs-eugenio-medea.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

IRCCS Eugenio Medea — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IRCCS Eugenio Medea pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Infectious Disease · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Laboratoires NEGMA · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
The HIV Netherlands Australia Thailand Research Collaboration · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IRCCS Eugenio Medea:

Cite this brief

Drug Landscape (2026). IRCCS Eugenio Medea — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/irccs-eugenio-medea. Accessed 2026-06-10.